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Abstract. Background/Aim: Recently, a set of studies
addressed the question of the prevalence of aberrant
methylation in surrogate tissues, such as peripheral blood
leukocytes. Toward this aim, we conducted a case-control pilot
study to investigate aberrant methylation in leukocytes of
gastric cancer patients. Materials and Methods: The SNuPE
combined with ion pair reverse phase HPLC (SIRPH method)
was used to examine site-specific methylation status at selected
CpG sites of the promoter regions of APC, ACIN1, BCL2,
CD44, DAPK1, CDKN2A, RARB, TNFRSF10C HS3ST2 and
of LINE-1, Alu repeats. Results: We observed that in the
patients, tumor suppressor genes were slightly but significantly
higher methylated at several CpG sites, while DNA repetitive
elements were slightly less methylated compared to controls.
This was found to be significantly associated with higher
prevalence for gastric cancer. Conclusion: These results
suggest that larger studies must be carried-out to explore the
biological significance and clinical usefulness of leukocyte
DNA as non-invasive detection tool for gastric cancer.
Gastric cancer is one of the leading causes of cancer-related
deaths worldwide with highest rates in Central and Eastern
Europe, although the incidence has gradually decreased in
many Western countries due to the recognition of certain risk
factors (e.g. low vegetable and fruit intake, high salt intake,
smoking, Helicobacter pylori) (1). Despite the
acknowledgement of the risk factors, the current 5-year
survival rate of individuals diagnosed with gastric cancer is
only 20-30%, with this low rate being attributable to the fact
that most cases are already in an advanced stage when
diagnosed. Therefore, the identification of early, accurate,
non-invasive biomarkers remains the promising approach for
improving the survival rate for gastric cancer patients.
Almost all gastric cancers have epigenetic abnormalities
that drive cancer development and progression in
collaboration with genetic changes leading to gain-of-function
in oncogenes and loss-of-function in tumor suppressor genes
(2, 3). However, a large body of evidence shows that genetic
alterations, particularly gene mutations, are relatively
infrequent in gastric cancer (4). 
Changes in the DNA methylation status, including global
DNA hypomethylation and site-specific gene hyper-
methylation, are concomitantly found in tumors and are the
most common molecular alterations in human neoplasia (5).
Most investigations of DNA methylation are based on the
assessment of differences in methylation levels between the
tumor and the adjacent tissues. In such cases access to the
affected tissue by surgery is required, which is a major
limitation for clinical utility.
There is growing evidence that methylation changes in
cancer patients arise systematically and may be measured in
surrogate tissues. Changes of methylation in leukocyte DNA
may reflect methylation levels within other tissues (6).
Methylation status could also be passed across generations
that may be affected by environmental exposures and aging
(7, 8). Therefore, studies investigating leukocyte DNA
methylation levels and cancer risk are rapidly emerging.
Although a large body of literature exists on DNA
methylation changes at the tissue level, less is known about
whether DNA methylation measured in leukocytes can be
used as a biomarker for different health outcomes. As blood
biomarkers can be measured repeatedly over time, they can
be useful to understand how disease risk changes over the life
course. At least ten studies measuring leukocyte DNA global
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methylation in different cancer types including stomach (9,
10), colon (11, 12), breast (13), bladder (14-16), head and
neck (17), renal cell (18) and pancreatic cancer (10) have
found an elevated risk for cancer between those in the lowest
quantile of global DNA methylation compared to those in the
highest quantile of risk. Only few studies on gene-specific
methylation in leukocyte DNA and cancer risk have focused
on specific genes for breast and colon cancers with their
results supporting the potential of gene-specific methylation
measured in leukocytes as a biomarker of disease risk (20-
25). These results demonstrate that methylation status in
leukocyte DNA may provide a useful biomarker for early
detection of cancer and, unlike tumor DNA, can be obtained
noninvasively and relatively inexpensively. 
Therefore, the aim of the present pilot study was to
determine whether selected tumor suppressor genes and
genome-wide repetitive sequence methylation in peripheral
blood leukocytes of subjects with gastric cancer and healthy
controls are different. An additional aim was to look for the
correlation of the methylation levels with the clinical and
morphological features.
Materials and Methods
Ethic statement. The study was approved by the Lithuanian Bioethics
Committee (reference number BE-2-17) and written informed
consents were obtained from all patients.
Gene selection. We selected genes of different metabolic pathways, as
certain genes, which are involved in cellular pathways such as signal
transduction, apoptosis, cell-to-cell communication, cell cycles and
cytokine signaling, are down-regulated in cancers and may be
considered as potential tumor suppressor genes (26). Therefore, we
investigated, CDKN2A (cyclin-dependent kinase inhibitor 2A; cell
cycle regulation) (27) and APC (Adenomatosis polyposis coli; signal
transduction) (28) as they have been shown to be methylated at
variable frequencies in gastric cancer (29) and apoptotic genes:
DAPK1 (Death-associated protein kinase 1), HS3ST2 (heparan sulfate
(glucosamine) 3-O-sulfotransferase 2; cell growth, adhesion and
migration) (30), RARB (Retinoic acid receptor beta; DNA binding,
activation transcription) (31), TNFRSF10C (Tumor necrosis factor
receptor superfamily member 10C), BCL2 (B-cell leukemia/lymphoma
2) (32-34), CD44 (CD44 antigen molecule; adhesion of cells to the
extracellular matrix) (35) and ACIN1 (apoptotic chromatin
condensation inducer 1). The latter genes (TNFRSF10C, BCL2, CD44,
ACIN1) were selected as they are frequently methylated in other
human cancers (29, 32-34). For surrogate markers of global
methylation, we selected long-interspersed elements (LINE-1) and the
most abundant short-interspersed elements in the human genome (Alu).
Both of these repetitive sequences account for 28% of the human
genome and normally they are heavily methylated. 
DNA samples. This study included 24 gastric cancer patients
diagnosed at the Department of Surgery (Hospital of Lithuanian
University of Health Sciences Kauno Klinikos, Lithuania) between
August 2005 and January 2007. All diagnoses were based on histo-
pathological evidence. The clinical and pathological characteristics
of these gastric cancer patients based on the Union for International
Cancer Control TNM classification (36) are summarized in Table I.
Patients had neither been submitted to chemotherapy or radiotherapy
prior to surgery, nor did they have any other diagnosed cancer. Blood
samples were taken immediately prior to surgery. The control
population consisted of 49 patients with benign diseases (12 with
inguinal hernias, 8 with primary ventral hernias and 29 with
cholelithiasis). There were no changes of inflammatory status in
control individuals. 
DNA extraction. Five milliliters corresponding to peripheral venous
blood were available from each out of twenty-four patients with
gastric cancer. Forty-nine peripheral venous blood samples were
obtained from the control population. Genomic DNA was extracted
from the peripheral blood by DNeasy® Blood and Tissue Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
recommendation. The DNA concentration was measured using
NanoDrop1000 (Thermo Scientific, Wilmington, USA).
Bisulfite modification, polymerase chain reactions and site-specific
methylation by SIRPH analysis. Two hundred ng of genomic DNA
was subjected to bisulfite conversion with the EpiTect Bisulfite kit
(Qiagen) according to manufacturer’s recommendation. Methylation-
specific polymerase chain reactions (PCR) with primers covering the
site of interest were performed essentially as previously described
(19). The site-specific quantitative methylation analysis at selected
CpG sites were done by using single-nucleotide primer extension
(SNuPE) and separation by ion-pair reverse-phase (IP RP) high-
performance liquid chromatography (SIRPH method) as previously
described by El-Maarri (37, 38). SNuPE primers used in this study
are as previously described (19). 
Data analysis. Descriptive analyses were performed on age, gender
between cases and controls and on clinical characteristics in gastric
cancer case group. Differences in methylation level values between
cases and controls were analyzed by the Mann-Whitney test. The
binary logistic regression analysis was used to determine associations
of the methylation status with various clinical and pathological
features. To evaluate the effects of site-specific CpG methylation
levels on case control status, while controlling for inter-variable
confounding, logistic regression was performed to determine odds
ratios (OR) and their associated 95% confidence intervals (CI). In
this analysis, site-specific CpG relative methylation level was broken
into tertiles based on the distribution in controls. p<0.05 was
considered as significant. Data were analyzed using the SPSS
statistical software, version 17.0.0 (SPSS Inc., Chicago, USA). The
hierarchical clustering as well as the principle component analysis
(PCA) was done using the Qlucore Omics Exlorer version 2.3.
(Qlucore, Lund, Sweden). 
Results
In the present study, we investigated the locus-specific
methylation at selected CpGs at Alu and LINE-1 repeats and
at promoter regions of nine tumor suppressor genes. We
measured methylation at three CpG sites in the Alu consensus
sequence, and at two CpG sites at LINE-1. For tumor
suppressor genes we measured one CpG site in the APC,
BCL2, DAPK1, TNFRSF10C, CD44 promoter region, and two
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CpG sites were measured in the CDKN2A, HS3ST2, ACIN1
and RARB promoter regions. Control patients used in this
study were matching the cases in both age and gender
distribution (Table I). 
Peripheral blood-derived DNA methylation analysis. The
average methylation levels at each CpG site for both cases and
controls blood derived DNA are summarized in Table II. Mean
methylation level at Alu and LINE-1 repeats in patients was
slightly lower than the mean level in the controls. Methylation
difference was significant (p<0.01) for all investigated CpGs.
The opposite methylation phenomenon was observed at tumor
suppressor genes. Mean methylation level was significantly
(p<0.05) higher in patients than in controls at CpGs of APC,
DAPK1, BCL2, CD44, TNFRSF10C and at one of two (i.e.
SN1) investigated CpGs of ACIN1 gene.
Association of peripheral blood relative methylation with
prevalence of gastric cancer. As we observed significant
differences in blood methylation between patients and healthy
controls, we performed binary logistic regression analysis to
examine the association between relative methylation level at
each of the investigated regions (gene promoter regions and
repetitive elements) and the presence of gastric cancer. In this
model, methylation was categorized into three groups divided
at the 33rd and 66th percentiles, with the highest tertile of
relative methylation serving as reference for Alu and LINE-
1. The lowest tertile served as the referent for promoters of
tumour suppressor genes CDKN2A, APC, 30ST2, DAPK1,
ACIN1, BCL2, CD44, RARB, TNFRSCF10C. We observed
that cases in the lowest tertile of LINE-1 SN1 (OR 6.7,
95%CI 1.7-26.6) relative methylation had a significantly
higher prevalence of gastric cancer (Figure 1). Similar
findings were observed in the lowest tertile of Alu CpGs: SN1
(OR 10.3, 95%CI 2.2-48.6), SN3 (OR 8.6, 95%CI 2.0-37.3)
and SN4 (OR 10.3, 95% CI 2.2-48). 
The highest relative methylation tertile of six tumor
suppressor genes promoter regions were associated with the
increased prevalence of gastric cancer (Figure 1). Single
investigated CpG of APC SN1 (OR 3.6, 95% CI 1.1-12.6),
DAPK1 (OR 3.9, 95% CI 1.1-13.9), ACIN1 SN1 (OR 30.9,
95% CI 3.6-265.4), BCL2 (OR 8.0, 95% CI 2.0-32.6), CD44
(OR 10.9, 95% CI 2.3-51) and TNFRSF10C (OR 8.1, 95% CI
1.9-33.6) were associated with gastric cancer as well as the
middle relative methylation tertile of RARB SN2 (OR 8.9,
95% CI 1.8-43). However, there were no associations between
methylation levels of CDKN2A, HS3ST2 and prevalence of
gastric cancer. It should be noted that methylation levels of the
latter two genes also were not significantly different, when
comparing between patients and controls. 
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Table I. Clinical characteristics of patients included in this study.
Cases Controls
n % n %
Age (years) <65 16 66.7 30 61.2
>=65 8 33.3 19 38.8
Gender Female 9 37.5 30 61.2
Male 15 62.5 19 38.8
Cancer stage* I+II 10 41.7
III+IV 14 58.3
pT category pT1+pT2 11 45.8
pT3+pT4 13 54.2
Lymph node involvement Negative 4 16.7
Positive 20 83.3
Distant metastases Negative 19 79.2
Positive 5 20.8
Invasion into blood vessels Negative 9 37.5
Positive 15 62.5
Invasion into lymph vessels Negative 4 16.7
Positive 20 83.3
Perineural spread Negative 8 33.3
Positive 16 66.7
Cell differentiation grade G1+G2 7 29.2
G3+G4 17 70.8
Hystological type Tubular 8 33.3
Poor diff., signet, 16 66.7
mucinous
*According to UICC 2009.
Table II. The comparison of peripheral blood-derived DNA mean
methylation in cases and controls.
Site Primer Control group Gastric cancer 
group
Mean SD Mean SD p-Values*
LINE-1 SN-1 51.99 0.70 50.50 1.70 <0.0001
SN-8 61.65 0.98 60.36 2.19 0.0036
Alu SN-1 30.02 2.57 26.93 1.23 <0.0001
SN-3 34.53 1.41 31.18 3.33 <0.0001
SN-4 36.95 1.30 35.29 1.02 <0.0001
CDKN2A SN-1 5.14 1.02 4.53 1.34 0.0629
SN-2 24.24 5.66 29.05 15.81 0.4884
APC SN-1 5.35 .96 7.32 2.32 0.0008
HS3ST2 SN-1 10.96 2.86 10.88 2.52 1.0000
SN-2 21.00 6.30 20.74 3.56 0.7691
DAPK1 SN-3 11.93 3.01 14.19 3.77 0.0132
ACIN1 SN-1 8.85 0.50 12.26 1.58 <0.0001
SN-3 16.39 2.68 16.27 1.02 0.1659
BCL2 SN-1 3.66 1.45 5.94 2.58 <0.0001
CD44 SN-2 3.33 0.41 4.23 1.08 <0.0001
RARB SN-1 7.59 4.49 7.24 1.69 0.3878
SN-2 5.38 4.09 6.63 1.71 0.2665
TNFRSF10C SN-1 4.92 3.59 5.27 0.40 <0.0001
*Mann-Whitney test.
The association of peripheral blood methylation with clinical
and morphological features. Next, we searched for
relationship between clinical and morphological features
(Table I) and hypomethylation or hypermethylation of all
studied loci. For this analysis, we grouped the highest and the
middle tertiles for the repetitive elements as well as the lowest
and the middle tertile for genes in the CpG island loci into
one variable. High level of DAPK1 SN3 methylation was
significantly associated with higher cancer pT category (OR
21, 95%CI 1.9-227.2) and higher stage according to UICC
(OR 9, 95% CI 1.3-63.9). High level of RARB SN2
methylation was significantly associated with cancer cell low-
grade of differentiation (OR 0.03, 95% CI 0.02-0.34). 
Hierarchical clustering and principle component analysis of
peripheral blood samples. In total 24 and 49 blood samples
corresponding to gastric tumor patients and healthy controls,
respectively, were used for the hierarchical cluster analysis.
When taking all the methylation data as input in an
unsupervised hierarchical clustering we could distinguish
one major cluster group containing 13 gastric patient blood
samples (or about 54%) (Figure 2A and B); four others
small clusters (of two to three) corresponding to the gastric
patients could also be distinguished. However, differential
methylation analysis to distinguish the blood of gastric
patients from healthy controls (at t-test p-value of 1.5×10–5
and false discovery rate (FDR) of <3.3×10–5) could
distinguish a major cluster containing 20 (83%) gastric
patient blood samples and a two minor cluster of 2 samples
each (Figure 2C and D). The PCA analysis could clearly
distinguish both groups of healthy control blood and gastric
cancer patients; however, the two groups appear continuous
and close to each other and separated in the middle by an
interface that contain mixed samples from both healthy and
tumor groups that are quite close in space. Therefore, based
only on 10 CpG sites, most of the samples could be
efficiently clustered into two groups.
Discussion
In the present study, we examined peripheral blood DNA to
determine whether changes in methylation at various CpG
sites of tumor suppressor genes and repetitive elements are
correlated with gastric cancer. We demonstrated highly
ANTICANCER RESEARCH 34: 5381-5388 (2014)
5384
Figure 1. The association of blood-derived DNA high methylation level at specific CpG sites and low methylation level at repetitive DNA elements
with prevalence of gastric cancer. Dots indicate odds ratio (value) and whiskers 95% CI. Lowest tertile is set as reference (1.0) trend line for gene
specific CpG sites. Highest tertile is set as reference trend line for repetitive DNA elements. Forrest plot presented in logarithmic scale. RARB*-
middle tertile. 
significant hypomethylation at repetitive DNA elements as
well as significant hypermethylation at specific loci in
leukocyte DNA of the patients with gastric cancer.
Importantly, we found that methylation differences were
significant across the clinical and morphological features of
the disease, suggesting that the differentially-methylated CpG
signatures may be useful for early diagnosis.
To date, only few cases–control studies have examined
gastric cancer risk in relation to both Alu and LINE-1
methylation. A Polish case–control study found gastric cancer
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Figure 2. Hierarchical clustering and PCA analysis: unsupervised hierarchical clustering (A) and PCA plot (B) of all CpG sites and all samples.
Differential methylation analysis of blood samples of healthy and gastric sample patients at a t-test p-value of 1.5×10–5 and FDR of <3.3×10–5; C)
hierarchical clustering of 10 CpG sites above the selected p-values; D) PCA plot showing clear separation.
risk to be highest among those with lowest level of
methylation in either Alu or LINE-1 (10). The results from
another study suggested that DNA methylation of Alu, but not
LINE-1, in blood leukocytes might be inversely associated
with risk of gastric cancer (9). In the present study, we found
significant methylation differences between patients, suffering
from gastric cancer and controls in all the 5 LINE-1 and Alu
studied CpGs. The association with gastric cancer prevalence
was confirmed with all investigated Alu CpGs and with one
LINE-1 CpG. Taken together these three studies, the divergent
associations with Alu and LINE-1 raise the possibility that the
roles of repetitive DNA methylation are different in gastric
cancer pathogenesis. There were no statistical differences in
the methylation levels by clinical and morphological features
of gastric cancer. Therefore, our findings suggest that the loss
of LINE-1 and Alu methylation, in blood, may occur more
significantly at the early onset of carcinogenesis and thus be
rather the marker of tumor initiation than the progression of
the disease. Another explanation, however, might be that the
small number of cases in the subgroups did not allow us to
detect more associations.
The few studies that exist on gene-specific methylation in
leukocytes and cancer risks have mostly focused on selected
genes for breast, colon and pancreatic cancer but they also
support the potential for gene-specific methylation measured
in leukocytes as a biomarker of risk (19, 21-24).
Widschwendter et al. examined locus-specific methylation
and found that particular DNA methylation patterns in
peripheral blood may serve as surrogate markers for breast
cancer (24). In a small cell lung cancer study, methylation
profiling analysis in leukocyte DNA identified two CpG sites
that discriminated cancer patients from control population
(39). Pedersen et al. built a prediction model consisting of
five CpG sites that discriminated pancreatic cancer patients
from controls (23). Our previous study revealed that in the
blood of patients with pancreatic ductal adenocarcinoma
tumor suppressor gene sites were slightly but significantly
higher methylated at several selected CpG sites (19). Also,
there are published studies with contradictory results. The
findings of the cross-sectional study by Cui et al. suggest that
measurements of insulin-like growth factor-II (IGF-II)
methylation status in lymphocytes could be used for the
prediction of colorectal cancer risk (40). Controversially,
another larger prospective study did not find any relationship
between colon cancer risk and methylation levels at CpGs of
IGF-II and thus does not support the hypothesis that colon
cancer can be predicted from the different levels of
methylation of the IGF-II gene from lymphocyte DNA (22).
However, available data are still very limited, and
systematic or unbiased approach to the selection of genes has
not been routinely employed (a large genome wide study is
needed). We have selected genes of different metabolic
pathways as they are considered potential tumor suppressor
genes. Among these genes, at least five were reported to be
associated with gastric cancer (29, 41-44). According to our
results, methylation levels of various genes were slightly, but
significantly higher in the blood of gastric cancer patients and
associated with the presence of gastric cancer. High
methylation levels of DAPK1 and RARB in peripheral blood
were found to be associated with a more advanced stage of the
disease and with poor cancer cell differentiation grade,
respectively. Interestingly, the results from studies on gastric
cancer tissues are partly consistent with our findings from
peripheral blood DNA. DAPK1 promoter hypermethylation in
cancer tissue was previously found to be associated with
advanced stage of gastric cancer (41) and RARB promoter
hypermethylation is a frequent finding in gastric cancerous
tissue, but not in association with cancer cell differentiation
grade (44-46). 
It is important that future studies address the molecular
mechanisms that lead to methylation changes in leukocytes
DNA of cancer patients since it is not clear whether the
observed methylation changes in leukocytes represent a cause
or consequence of the disease. We also cannot completely
rule-out the possibility that our observations may be biased
by the impact of some other unknown to us concomitant
chronic diseases in our patients. While this is an exciting area
of investigation, clearly more input is needed to fully
understand and appreciate the findings in leukocytes.
When interpreting our results, it is important to rule-out
circulating tumor cell or free-cell DNA which could influence
the methylation results, because both are increased in cancer
patients (47). The peripheral blood samples used in this study
were obtained after the diagnosis of gastric cancer before any
specific treatment and before surgery. It is worth to note, that
most cases were without distant metastases at the time of
surgery. However, even in patients with metastatic gastric
cancer, an average of 24 tumor cells out of 4.5 million white
blood cells in 7.5 ml of peripheral blood are the circulating
tumor cells (47). The possibility that the methylation
differences we have detected in peripheral blood cell DNA
might be influenced or originated from tumor cell DNA can
be completely excluded. Moreover, the blood was centrifuged
before DNA extraction, with only the isolated nuclei used in
the DNA extraction. Therefore, the influence of free plasma
DNA is also not relevant.
However, this study has certain limitations. First, we tested
only one to two CpG sites per gene. The findings could
indicate that not all CpG sites are equal in cancer risk
prediction and that a larger number of CpGs that cover a more
extensive area of the CpG island should be studied to provide
higher predictive values. Second, we were unable to determine
possible mechanisms influencing methylation differences
between cases and controls, including genetics, nutrition,
enviromental pollution and sub-population of leukocytes. Third,
the clinical sample size is small. Larger studies are clearly
ANTICANCER RESEARCH 34: 5381-5388 (2014)
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required to confirm the significance of aberrant methylation in
peripheral blood leukocytes. Also, further investigations should
be focused on the estimation whether the observed differences
occur prior to, or as a result of, carcinogenesis and whether
changes in leukocyte DNA methylation are associated with
disease risk changes over the lifetime.
In conclusion, we showed that methylation levels and
patterns could be used to distinguish most cases of gastric
cancer from healthy controls. Although this pilot study is limited
by both the number of patients and number of loci studied, it
nevertheless shows that more studies should be undertaken in
this direction. This could lead to more accurate and sensitive
methods for non-invasive early detection of cancer.
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